Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New biologic shows promise for rare inflammatory disease in japan

NCT ID NCT04717635

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested canakinumab, an anti-inflammatory biologic, in 14 Japanese adults with Adult-Onset Still's Disease (AOSD), a rare condition causing fevers and joint pain. Participants received injections every 4 weeks for at least 48 weeks. The goal was to see if the drug could improve symptoms and help patients reduce their steroid use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
canakinumab (a biologic drug that blocks inflammation)
What this could lead to
If it works, this could provide a new treatment option for Japanese patients with Adult-Onset Still's Disease, helping control symptoms and reduce steroid use.
What could go wrong
This was a small, single-arm study with only 14 participants, so results may not apply broadly. As a biologic, canakinumab carries risks like increased infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

14 people

The number who actually took part.

Started

Mar 2021

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent had to be obtained prior to participation in the study. Parent's or legal guardian's written informed consent and child's assent, if appropriate, were required before any assessment was performed for participants \< 20 years of age. * Japanese male and female participants aged ≥ 16 years were eligible. * Diagnosis of AOSD had to be confirmed as per Yamaguchi criteria, with disease onset at ≥ 16 years of age. The Yamaguchi criteria required at least five criteria, including two major criteria and no exclusion criteria. * Participants had to have active disease at baseline, defined as follows: * Fever (body temperature \> 38°C) due to AOSD for at least 1 day within 1 week before baseline * At least 2 active joints (tender or swollen) * CRP ≥ 10 mg/L Exclusion Criteria: * Pregnant or nursing (lactating) female participants were excluded. Pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL) at the screening visit. * Participants with a history of significant hypersensitivity to the study drug or to biologics were excluded. * Participants with a history or evidence of active macrophage activation syndrome or disseminated intravascular coagulation within 6 months prior to enrollment were excluded. * Participants with underlying metabolic, renal, hepatic, infectious, or gastrointestinal conditions that, in the opinion of the investigator, compromised the participant and/or placed the participant at unacceptable risk for participation in immunomodulatory therapy were excluded. * Participants with active or recurrent bacterial, fungal, or viral infections at the time of enrollment, including evidence of HIV infection, Hepatitis B, or Hepatitis C, were excluded. * Participants with an absolute neutrophil count \< 1500/mm³ at screening were excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult-onset Still's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Chiba, Chiba, 260 8677, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0608648, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa-ku, 236-0004, Japan

  • Novartis Investigative Site

    Iruma-gun, Saitama, 3500495, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, 1138655, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 1048560, Japan

  • Novartis Investigative Site

    Mitaka, Tokyo, 181-8611, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1608582, Japan

  • Novartis Investigative Site

    Ishikawa, 9208641, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.